Skip to search formSkip to main contentSkip to account menu

CC-486

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Oral Azacitidine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer
Purpose CC-486 is an oral formulation of azacitidine that allows for extended dosing schedules to prolong azacitidine exposure to… 
2018
2018
Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08)
Background: For patients with diffuse large B-cell lymphoma (DLBCL), resistance to standard R-CHOP immunochemotherapy remains… 
2017
2017
A phase II study of oral azacitidine (CC-486) in combination with pembrolizumab (PEMBRO) in patients (pts) with metastatic melanoma (MM).
9560 Background: Immune checkpoint blockade (ICB) have improved survival for many pts with MM, offering durable responses in up… 
2017
2017
Final Analysis of the Phase I/II Study of CC-486 (Oral Azacitidine) Maintenance Therapy after Allogeneic Stem Cell Transplantation (Allo-SCT) in Patients with Acute Myeloid Leukemia (AML) or…
Background: Most relapses occur within 1 year post-transplant and relapse is the major cause of treatment (Tx) failure after allo… 
2016
2016
CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies
Background: Injectable HMAs (azacitidine [AZA], decitabine) are the standard of care in higher-risk myelodysplastic syndromes (HR… 
2016
2016
A phase II multicenter, randomized, placebo-controlled, double-blind study of CC-486 plus pembrolizumab (pembro) vs pembro plus placebo (PBO) in previously treated patients (pts) with locally…
TPS9107Background: Effective second-line chemotherapeutic treatment options for pts with NSCLC are limited. Pembro, a PD-1… 
2015
2015
CC-486 (Oral Azacitidine) Monotherapy in Patients with Acute Myeloid Leukemia (AML)
Background: When administered subcutaneously (SC), the epigenetic modifier, azacitidine (AZA) is shown to improve overall… 
2014
2014
Pharmacokinetics of different formulations of oral azacitidine (CC‐486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies
Parenteral azacitidine improves overall survival in higher‐risk myelodysplastic syndromes. An oral azacitidine formulation would… 
2014
2014
CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)
Background : Disease relapse and graft vs host disease (GvHD) following alloHSCT are major causes of treatment (Tx) failure in… 
2012
2012
Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes
Abstract 424 Background: Azacitidine for injection has been shown to prolong overall survival in patients (pts) with higher-risk… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)